Predicting and preventing the future: actively managing multiple sclerosis.

Hdl Handle:
http://hdl.handle.net/10147/207018
Title:
Predicting and preventing the future: actively managing multiple sclerosis.
Authors:
Hutchinson, Michael
Affiliation:
Department of Neurology, St Vincent's University Hospital, Elm Park, Dublin 4,, Ireland. mhutchin@iol.ie
Citation:
Pract Neurol. 2009 Jun;9(3):133-43, discussion 144.
Journal:
Practical neurology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207018
DOI:
10.1136/jnnp.2009.177212
PubMed ID:
19448055
Abstract:
Relapsing-remitting multiple sclerosis (MS) has a highly variable clinical course but a number of demographic, clinical and MRI features can guide the clinician in the assessment of disease activity and likely disability outcome. It is also clear that the inflammatory activity in the first five years of relapsing-remitting MS results in the neurodegenerative changes seen in secondary progressive MS 10-15 years later. While conventional first-line disease modifying therapy has an effect on relapses, about one third of patients have a suboptimal response to treatment. With the advent of highly active second-line therapies with their evident marked suppression of inflammation, the clinician now has the tools to manage the course of relapsing-remitting MS more effectively. The development of treatment optimisation recommendations based on the clinical response to first-line therapies can guide the neurologist in more active management of the early course of relapsing-remitting MS, with the aim of preventing both acute inflammatory axonal injury and the neurodegenerative process which leads to secondary progressive MS.
Language:
eng
MeSH:
Age of Onset; Female; Forecasting; Humans; Immunologic Factors/therapeutic use; Inflammation/physiopathology/prevention & control; Interferon-beta/therapeutic use; Male; Multiple Sclerosis/drug therapy/physiopathology/*prevention & control/*therapy; Multiple Sclerosis, Relapsing-Remitting/prevention & control/therapy; Sex Characteristics
ISSN:
1474-7766 (Electronic); 1474-7758 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorHutchinson, Michaelen_GB
dc.date.accessioned2012-02-01T10:28:20Z-
dc.date.available2012-02-01T10:28:20Z-
dc.date.issued2012-02-01T10:28:20Z-
dc.identifier.citationPract Neurol. 2009 Jun;9(3):133-43, discussion 144.en_GB
dc.identifier.issn1474-7766 (Electronic)en_GB
dc.identifier.issn1474-7758 (Linking)en_GB
dc.identifier.pmid19448055en_GB
dc.identifier.doi10.1136/jnnp.2009.177212en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207018-
dc.description.abstractRelapsing-remitting multiple sclerosis (MS) has a highly variable clinical course but a number of demographic, clinical and MRI features can guide the clinician in the assessment of disease activity and likely disability outcome. It is also clear that the inflammatory activity in the first five years of relapsing-remitting MS results in the neurodegenerative changes seen in secondary progressive MS 10-15 years later. While conventional first-line disease modifying therapy has an effect on relapses, about one third of patients have a suboptimal response to treatment. With the advent of highly active second-line therapies with their evident marked suppression of inflammation, the clinician now has the tools to manage the course of relapsing-remitting MS more effectively. The development of treatment optimisation recommendations based on the clinical response to first-line therapies can guide the neurologist in more active management of the early course of relapsing-remitting MS, with the aim of preventing both acute inflammatory axonal injury and the neurodegenerative process which leads to secondary progressive MS.en_GB
dc.language.isoengen_GB
dc.subject.meshAge of Onseten_GB
dc.subject.meshFemaleen_GB
dc.subject.meshForecastingen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunologic Factors/therapeutic useen_GB
dc.subject.meshInflammation/physiopathology/prevention & controlen_GB
dc.subject.meshInterferon-beta/therapeutic useen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMultiple Sclerosis/drug therapy/physiopathology/*prevention & control/*therapyen_GB
dc.subject.meshMultiple Sclerosis, Relapsing-Remitting/prevention & control/therapyen_GB
dc.subject.meshSex Characteristicsen_GB
dc.titlePredicting and preventing the future: actively managing multiple sclerosis.en_GB
dc.contributor.departmentDepartment of Neurology, St Vincent's University Hospital, Elm Park, Dublin 4,, Ireland. mhutchin@iol.ieen_GB
dc.identifier.journalPractical neurologyen_GB
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.